Company Overview and News

 
MGC Pharmaceuticals attracts $5 million for medical cannabis facility in Malta

2018-04-11 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd (ASX:MXC) has successfully raised over $5 million via a share placement to sophisticated and professional investors at 7 cents per share.

 
MGC Pharmaceuticals commencing production of CannEpil for epilepsy

2018-03-28 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd (ASX:MXC) is today commencing production of its first batch of CannEpil at its European medicinal cannabis facility.

 
MGC Pharmaceuticals commencing production of CannEpil

2018-03-28 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd (ASX:MXC) is today commencing production of its first batch of CannEpil at its European medicinal cannabis facility.

 
Weekly Cannabis Report: Nasdaq Listing = 37% Pop In Share Price

2018-03-05 seekingalpha
Welcome to our Weekly Cannabis Report, a reliable source for investors to receive the latest developments and critical analysis for the cannabis sector.

 
MGC Pharmaceuticals launches cannabidiol cream for psoriasis

2018-01-04 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd (ASX:MXC) has launched its first Derma Plus product -  Herbal Repair Cream containing cannabidiol (CBD) compounds, used for the daily relief of mild forms of psoriasis.

 
MGC Pharmaceuticals and Petrel Energy are the ASX Most Active, but head in different directions

2017-10-23 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd (ASX:MXC) and Petrel Energy Ltd (ASX:PRL) are the two most active stocks on the ASX, by far, and for two very different compelling reasons.

 
MGC in Korean supply deal

2017-10-20 businessnews.com.au
Medical cannabis company MGC Pharmaceuticals has locked in a supply agreement that it expects to net about $20 million in annual revenue from.

 
MGC Pharmaceuticals tops the ASX Most Traded on back of medical cannabis revenues

2017-10-20 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd (ASX:MXC) has traded 88 million shares in the first 45 minutes of trade, with the stock jumping 71% to $0.065.

 
MGC Pharmaceuticals’ medicinal cannabis plants enter flowering phase

2017-10-13 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd’s (ASX:MXC) Czech Republic operation is progressing well with over 450 medicinal cannabis plants entering the flowering phase.

 
MGC Pharmaceuticals’ medicinal cannabis plants enters flowering phase

2017-10-13 proactiveinvestors.com.au
MGC Pharmaceuticals Ltd’s (ASX:MXC) Czech Republic operation is progressing well with over 450 medicinal cannabis plants entering the flowering phase.

 
MGC Pharmaceuticals aims to develop new medicinal cannabis strains

2017-06-05 proactiveinvestors.com.au
MGC Pharmaceuticals (ASX:MXC) has signed an agreement with the University of Ljubljana in Slovenia to commence a 3-year comprehensive botanical research program.

 
Brian Gaynor: Cannabis stocks don't take long to get high

2017-05-12 nzherald.co.nz
Global sharemarkets are going to pot as a large number of marijuana companies have listed in recent years, including on the Australian sharemarket.

 
MGC Pharmaceuticals appoints Roby Zomer as CEO

2017-05-10 proactiveinvestors.com.au
Roby Zomer is one of these founders, and he has now been promoted to chief executive officer.

 
MGC Pharmaceuticals to reveal medical cannabis agreement

2017-05-01 proactiveinvestors.com.au
MGC Pharmaceuticals (ASX:MXC) is some interesting news pending with the execution of a material strategic agreement with the Royal Melbourne Institute of Technology (RMIT).

 
How high is too high for Australia's cannabis stocks?

2017-04-28 theage.com.au
Perhaps it shouldn't be surprising that wacky things keep happening in Australia's nascent legal cannabis industry.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...